Approximately 8.3 million prescriptions were written to Medicaid patients for the branded respiratory medicine Ventolin HFA in 2017, which was an increase of around 1.3 million on the previous year. Prescriptions for Montelukast Sodium and Albuterol Sulfate also increased between 2016 and 2017.
What is Ventolin HFA used for?
Ventolin HFA is an inhaled medicine used to treat or prevent bronchospasm in patients with reversible obstructive airway disease, which is a type of respiratory disease. Examples of obstructive airway disease include asthma and bronchitis. Ventolin HFA is branded by global pharmaceutical company GlaxoSmithKline and was one of the leading asthma medicines worldwide in 2018.
COVID-19: An infectious respiratory disease
Coronaviruses, such as the one that causes COVID-19, can give rise to mild respiratory infections, and people might experience symptoms that include a cough, fever, and difficulty breathing. However, for some individuals with underlying medical conditions, the risks are higher. People with asthma or bronchitis are more vulnerable and have been advised to take extra steps to protect themselves. In the United States during March 2020, asthma was commonly reported as a pre-existing condition among patients who were hospitalized with COVID-19 symptoms.
Number of common Medicaid respiratory agent prescriptions annually in 2016 and 2017, by product*
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Sanofi. (October 2, 2017). Number of common Medicaid respiratory agent prescriptions annually in 2016 and 2017, by product* [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/323185/common-medicaid-dispensed-respiratory-agent-prescriptions-by-drug-class/
Sanofi. "Number of common Medicaid respiratory agent prescriptions annually in 2016 and 2017, by product*." Chart. October 2, 2017. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/323185/common-medicaid-dispensed-respiratory-agent-prescriptions-by-drug-class/
Sanofi. (2017). Number of common Medicaid respiratory agent prescriptions annually in 2016 and 2017, by product*. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/323185/common-medicaid-dispensed-respiratory-agent-prescriptions-by-drug-class/
Sanofi. "Number of Common Medicaid Respiratory Agent Prescriptions Annually in 2016 and 2017, by Product*." Statista, Statista Inc., 2 Oct 2017, https://www-statista-com.ezproxy.canberra.edu.au/statistics/323185/common-medicaid-dispensed-respiratory-agent-prescriptions-by-drug-class/
Sanofi, Number of common Medicaid respiratory agent prescriptions annually in 2016 and 2017, by product* Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/323185/common-medicaid-dispensed-respiratory-agent-prescriptions-by-drug-class/ (last visited November 10, 2024)
Number of common Medicaid respiratory agent prescriptions annually in 2016 and 2017, by product* [Graph], Sanofi, October 2, 2017. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/323185/common-medicaid-dispensed-respiratory-agent-prescriptions-by-drug-class/
